Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis
(MF)
The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and
efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2
will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.